Post-COVID SARS-CoV-2 Antigen Persistence: A Critical Review of Mass Spectrometry Methodology and the Confound of Vaccine-Derived Antigens

Abstract

Persistent SARS-CoV-2 antigen has been proposed as a driver of post-COVID condition (PCC), with targeted mass spectrometry multiple reaction monitorin/selected reaction monitoring (MRM/SRM) increasingly invoked as quantitative evidence. We appraise the targeted-MS literature on SARS-CoV-2 antigen in genuine human clinical specimens and re-analyse a focal study, which reported spike and nucleocapsid “protein” concentrations in ng/µL from two proteotypic peptides per target with ¹³C/¹⁵N internal standards. These values are either physically impossible as intact protein or, more likely, raw peptide concentrations reported without the required ≈122-fold molecular-weight correction. Only 15 of 65 patients (26%) had cellular pellet spike above the authors’ own limit of quantification; nucleocapsid was essentially undetectable; and in those 15, the nucleocapsid: spike molar ratio was strongly inverted relative to intact virions, incompatible with a viral source. Critically, no targeted-MS method has ever quantified spike in human blood—the prior literature is nucleocapsid detection in respiratory specimens and spike quantification in vaccine or recombinant material—so the reported blood-spike values lack any validated precedent and exceed the most sensitive validated platform (single-molecule arrays) by several orders of magnitude, with no enrichment step. Finally, 77% of the cohort was vaccinated, and a measurable spike was concentrated among vaccinated individuals. The source’s own supplement inconsistently reports vaccination status. Their 2024 predecessor publication withheld it entirely. The MRM/SRM data, therefore, do not support persistent viral antigen as a general driver of PCC. Minimum standards are proposed: molar reporting, strict limit-of-quantification (LOQ) compliance, qualifier-ion confirmation, vaccine-discrimination peptides, stoichiometric cross-validation, and vaccination-status disclosure. We suggest that the cellular blood component, routinely discarded, warrants direct investigation in the context of spike persistence and PCC symptoms.

Keywords

Post-COVID condition / SARS-CoV-2 antigen persistence / Long COVID biomarkers / Targeted mass spectrometry / MRM/SRM / Spike protein quantification / Nucleocapsid protein detection / Quantitative proteomics

References

[1] Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023, 21, 133-146. DOI:10.1038/s41579-022-00846-2

[2] Ely EW, Brown LM, Fineberg HV. Long COVID. N. Engl. J. Med. 2024, 390, 2097-2108. DOI: 10.1056/NEJMsb2408466

[3] Parotto M, Gyöngyösi M, Howe K, Myatra SN, Ranzani O, Shankar-Hari M, et al. Post-Acute Sequelae of COVID-19: Understanding and addressing the burden of multisystem manifestations. Lancet Respir. Med. 2023, 11, 739-754. DOI:10.1016/S2213- 2600(23)00239-4

[4] Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin. Infect. Dis. 2023, 76, E487-E490. DOI:10.1093/cid/ciac722

[5] Craddock V, Mahajan A, Spikes L, Krishnamachary B, Ram AK, Kumar A, et al. Persistent circulation of soluble and extracellular vesicle-linked spike protein in individuals with postacute sequelae of COVID-19. J. Med. Virol. 2023, 95, e28568. DOI:10.1002/jmv.28568

[6] Peluso MJ, Swank ZN, Goldberg SA, Lu S, Dalhuisen T, Borberg E, et al. Plasma-based antigen persistence in the post-acute phase of COVID-19. Lancet Infect. Dis. 2024, 24, E345-E347. DOI:10.1016/S1473-3099(24)00211-1

[7] Arostegui D, Castro K, Schwarz S, Vaidy K, Rabinowitz S, Wallach T. Persistent SARS-CoV-2 nucleocapsid protein presence in the intestinal epithelium of a pediatric patient 3 months after acute infection. JPGN Rep. 2022, 3, e152. DOI:10.1097/pg9.0000000000000152

[8] Patterson BK, Yogendra R, Francisco EB, Guevara-Coto J, Long E, Pise A, et al. Detection of S 1 spike protein in CD16+ monocytes up to 245 days in SARS-CoV-2-negative post-COVID-19 vaccine syndrome (PCVS) individuals. Hum. Vaccines Immunother. 2025, 21, 2494934. DOI:10.1080/21645515.2025.2494934

[9] Bezstarosti K, Lamers MM, Doff WAS, Wever PC, Thai KTD, van Kampen JJA, et al. Targeted proteomics as a tool to detect SARS-CoV-2 proteins in clinical specimens. PLoS ONE 2021, 16, e0259165. DOI:10.1371/journal.pone.0259165

[10] Cardozo KHM, Lebkuchen A, Okai GG, Schuch RA, Viana LG, Olive AN, et al. Establishing a mass spectrometry-based system for rapid detection of SARS-CoV-2 in large clinical sample cohorts. Nat. Commun. 2020, 11, 6201. DOI:10.1038/s41467-020-19925-0

[11] Rajczewski AT, Mehta S, Nguyen DDA, Grüning B, Johnson JE, McGowan T, et al. A rigorous evaluation of optimal peptide targets for MS-based clinical diagnostics of Coronavirus Disease 2019 ( COVID-19). Clin. Proteom. 2021, 18, 15. DOI:10.1186/s12014-021-09321-1

[12] Cazares LH, Chaerkady R, Samuel Weng SH, Boo CC, Cimbro R, Hsu HE, et al. Development of a Parallel Reaction Monitoring Mass Spectrometry Assay for the Detection of SARS-CoV-2 Spike Glycoprotein and Nucleoprotein. Anal. Chem. 2020, 92, 13813-13821. DOI:10.1021/acs.analchem.0c02288

[13] Renuse S, Vanderboom PM, Maus AD, Kemp JV, Gurtner KM, Madugundu AK, et al. A Mass Spectrometry-Based Targeted Assay for Detection of SARS-CoV-2 Antigen from Clinical Specimens. EBioMedicine 2021, 69, 103465. DOI:10.1016/j.ebiom.2021.103465

[14] Suddhapas K, Choi MH, Shortreed MR, Timperman A. Evaluation of Variant-Specific Peptides for Detection of SARS-CoV-2 Variants of Concern. J. Proteome Res. 2022, 21, 2443-2452. DOI:10.1021/acs.jproteome.2c00325

[15] Pierce-Ruiz C, Santana WI, Sutton WJH, Fischler DA, Cooper HC, Marc LR, et al. Quantification of SARS-CoV-2 spike and nucleocapsid proteins using isotope dilution tandem mass spectrometry. Vaccine 2021, 39, 5106-5115. DOI:10.1016/j.vaccine.2021.07.066

[16] Gallien S, Duriez E, Domon B. Selected reaction monitoring applied to proteomics. J. Mass Spectrom. 2011, 46, 298-312. DOI:10.1002/jms.1895

[17] Carr SA, Abbatiello SE, Ackermann BL, Borchers C, Domon B, Deutsch EW, et al. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol. Cell Proteom. 2014, 13, 907-917. DOI:10.1074/mcp.M113.036095

[18] van den Broek I, Mastali M, Mouapi K, Bystrom C, Bairey Merz CN, Van Eyk JE. Quality control and outlier detection of targeted mass spectrometry data from multiplex protein panels. J. Proteome Res. 2020, 19, 2278-2293. DOI:10.1021/acs.jproteome.9b00854

[19] Seco-Gonzalez A, Antelo-Riveiro P, Bravo SB, Domínguez-Santalla MJ, Rodríguez-Ruiz E, Piñeiro Á, et al. Comprehensive molecular characterization of post-COVID condition: Immunoglobulin suppression and persistent SARS-CoV-2 antigens as key pathophysiological drivers. J. Infect. Public Health 2025, 18, 102870. DOI:10.1016/j.jiph.2025.102870

[20] Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020, 367, 1260-1263. DOI:10.1126/science.abb2507

[21] Ke Z, Oton J, Qu K, Cortese M, Zila V, McKeane L, et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 2020, 588, 498-502. DOI:10.1038/s41586-020-2665-2

[22] Brogna C, Cristoni S, Marino G, Montano L, Viduto V, Fabrowski M, et al. Detection of recombinant spike protein in the blood of individuals vaccinated against SARS-CoV-2: Possible molecular mechanisms. Proteom. Clin. Appl. 2023, 17, e2300048. DOI:10.1002/prca.202300048

[23] Heinz FX, Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines 2021, 6, 104. DOI:10.1038/s41541-021-00369-6

[24] Giesen C, Saa-Requejo C, Lopez-Carrillo I, Ortega-Torres A, García-Fernández C. Risks of adverse outcomes in COVID-19 patients and vaccination status in a secondary hospital in Spain. Vacunas 2022, 23, S32-S35. DOI:10.1016/j.vacune.2022.10.013

[25] Brogna C, Cristoni S. A new absolute quantitative method for peptide and metabolite detection. J. Mass Spectrom. 2024, 59, e4991. DOI:10.1002/jms.4991

[26] Bansal S, Perincheri S, Fleming T, Poulson C, Tiffany B, Bremner RM, et al. Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer-BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines. J Immunol. 2021, 207, 2405-2410. DOI:10.4049/jimmunol.2100637

[27] Rogers MA, Buffolo F, Schlotter F, Atkins SK, Lee LH, Halu A, et al. Annexin A1-dependent tethering promotes extracellular vesicle aggregation revealed with single-extracellular vesicle analysis. Sci. Adv. 2020, 6, eabb1244. DOI:10.1126/sciadv.abb1244

[28] Pavlova S, Mamand DR, Hagey DW, Liang X, Estupiñán HY, Zheng W, et al. Injected extracellular vesicles and other nanoparticles hitchhike on erythrocytes and platelets from circulation towards organ clearance. Extracell. Vesicle 2026, 7, 100103. DOI:10.1016/j.vesic.2025.100103

[29] Ogata AF, Maley AM, Wu C, Gilboa T, Norman M, Lazarovits R, et al. Ultra-sensitive serial profiling of SARS-CoV-2 antigens and antibodies in plasma to understand disease progression in COVID-19 patients with severe disease. Clin. Chem. 2020, 66, 1562-1572. DOI:10.1093/clinchem/hvaa213

[30] Bate N, Lane D, Evans SE, Salim F, Allcock NS, Haigh R, et al. Engineered Receptor Capture Combined with Mass Spectrometry Enables High-Throughput Detection and Quantitation of SARS-CoV-2 Spike Protein. JACS Au 2025, 5, 747-755. DOI:10.1021/jacsau.4c00980

[31] Seco-González A, Antelo-Riveiro P, Bravo SB, Garrido PF, Domínguez-Santalla MJ, Rodríguez-Ruiz E, et al. Proteomic analysis of post-COVID condition: Insights from plasma and pellet blood fractions. J. Infect. Public Health 2024, 17, 102571. DOI:10.1016/j.jiph.2024.102571